3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Unresectable Pancreatic Cancer
1
Stomach Neoplasms
1
Solid Tumor Including Thyroid, Bone, Liver, Pancreas
1
Locally Advanced Pancreatic Cancer
1
Liver Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Basal Cell
1
Interventions
Sunitinib
14
aldesleukin
10
Bevacizumab
8
pembrolizumab
7
Nivolumab
7
pazopanib
5
Axitinib
5
atezolizumab
4
Interferon-alpha
4
sintilimab
3
durvalumab
3
Sorafenib
3
Everolimus
3
Cyclophosphamide
3
Chemotherapy, Adjuvant
3
toripalimab
2
sargramostim
2
olaparib
2
lenvatinib
2
fludarabine phosphate
2
camrelizumab
2
avelumab
2
Neoadjuvant Therapy
2
Laparoscopy
2
Ipilimumab
2
Interferon alpha-2
2
Immunohistochemistry
2
Immune Checkpoint Inhibitors
2
Gene Expression Profiling
2
Fluorouracil
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Carcinoma, Renal Cell
×
Electroporation
×
Clear all
NCT01967407
2014-11-19
IRENE
University of Magdeburg
Phase 1/2
Unknown
20 enrolled